P225. Evaluation of the relationship between serum ghrelin, C-reactive protein and interleukin-6 levels and disease activity in inflammatory bowel diseases
C. Çekiç, S. Ipek, F. Aslan, E. Alper, B. Unsal, Katip Çelebi University, Atatürk Training and Research Hospital, Gastroenterology, Izmir, Turkey
In this study it was aimed to establish the relationship between serum ghrelin levels and disease activity in inflammatory bowel diseases, and also to compare the effectiveness of ghrelin levels, C-reactive protein and interleukin-6 levels in establishing disease activity.
52 cases with ulcerative colitis and 33 with Crohn' disease, total 85 patients, were included in this study. Disease activities were established by Crohn's disease activity index and ulcerative colitis Montreal classification criteria. The serum ghrelin levels of the patients in remission and of those with active disease were compared. Also, based on the disease activities, the effectiveness of serum ghrelin, interleukin-6 and C-reactive protein levels in establishing the severity of the disease were evaluated.
The mean serum ghrelin level in active patients (1243±648 pg/ml), was found to be higher than those in remission (466±214 pg/ml) (p < 0.001). In establishing the disease activity, it has been concluded that ghrelin is a much stronger marker compared to interleukin-6, however CRP is a much more effective marker compared to the other two inflammatory markers. AUC values were established as; CRP: 0.947 (95% CI, 0.903–0.992), ghrelin: 0.934 (95% CI, 0.884–0.984) ve interleukin-6: 0.756 (95% CI, 0.648–0.864).
Serum ghrelin levels can be an important marker in establishing disease activity in inflammatory bowel diseases. For the time being, more advanced studies are needed, in order to be able to use serum ghrelin levels as a routine test in establishing the mucosal damage in inflammatory bowel diseases.